We are live on ! Find out more
PHAT icon

Phathom Pharmaceuticals
PHAT

103 hedge funds and large institutions have $613M invested in Phathom Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 41 increasing their positions, 20 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

869% more call options, than puts

Call options by funds: $6.18M | Put options by funds: $638K

211% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 9

179% more capital invested

Capital invested by funds: $220M → $613M (+$393M)

150% more funds holding in top 10

Funds holding in top 10: 2 → 5 (+3)

105% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 20

23% more funds holding

Funds holding: 84 → 103 (+19)

4.79% more ownership

Funds ownership: 73.35% → 78.15% (+4.8%)

Holders
103
Holders Change
+19
Holders Change %
+22.62%
% of All Funds
1.62%
Holding in Top 10
5
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+150%
% of All Funds
0.08%
New
28
Increased
41
Reduced
20
Closed
9
Calls
$6.18M
Puts
$638K
Net Calls
+$5.54M
Net Calls Change
+$3.75M

Top Buyers

1
FLSM
Frazier Life Sciences Management
California
+$19.6M
2
MVM
Medicxi Ventures Management
Jersey
+$14.7M
3
NMC
NEA Management Company
Maryland
+$14.7M
4
Invesco
Invesco
Georgia
+$13.3M
5
KCM
Kennedy Capital Management
Missouri
+$12.1M

Top Sellers

1
OM
Opaleye Management
Massachusetts
-$3.54M
2
Bank of America
Bank of America
North Carolina
-$2.28M
3
Citadel Advisors
Citadel Advisors
Florida
-$1.98M
4
APM
Avidity Partners Management
Texas
-$1.14M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$957K
Name Holding Trade Value Shares
Change 		Change in
Stake
FLSM
1
Frazier Life Sciences Management
California
$145M +$19.6M +1,702,127 +20%
MVM
2
Medicxi Ventures Management
Jersey
$53.9M +$14.7M +1,276,595 +51%
CG
3
Carlyle Group
District of Columbia
$50.1M +$6.48M +561,702 +19%
Invesco
4
Invesco
Georgia
$47.7M +$13.3M +1,150,465 +53%
BlackRock
5
BlackRock
New York
$28.7M +$4.26M +369,722 +23%
APM
6
Avidity Partners Management
Texas
$27.9M -$1.14M -98,900 -5%
Ensign Peak Advisors
7
Ensign Peak Advisors
Utah
$25.2M -$46.9K -4,064 -0.2%
Vanguard Group
8
Vanguard Group
Pennsylvania
$25M +$6.51M +564,840 +48%
6CM
9
683 Capital Management
New York
$18.4M -$438K -38,000 -3%
NMC
10
NEA Management Company
Maryland
$18.3M +$14.7M +1,276,595 New
GGHC
11
Gilder Gagnon Howe & Co
New York
$15.2M +$5.84M +506,776 +92%
KCM
12
Kennedy Capital Management
Missouri
$15M +$12.1M +1,049,675 New
DCMIC
13
Decheng Capital Management III (Cayman)
Cayman Islands
$12.2M +$9.8M +850,000 New
EC
14
EcoR1 Capital
California
$10M +$8.07M +700,000 New
NM
15
Newtyn Management
New York
$9.79M +$18.7K +1,621 +0.2%
WP
16
Woodline Partners
California
$9.65M +$7.77M +673,688 New
DM
17
Deerfield Management
New York
$9.39M +$7.56M +656,000 New
GKIM
18
GW&K Investment Management
Massachusetts
$8.48M -$74.5K -6,460 -1%
State Street
19
State Street
Massachusetts
$7.59M +$762K +66,100 +14%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$7.02M +$479K +41,512 +9%
SG
21
StepStone Group
California
$6.04M – – –
MB
22
MPM BioImpact
Massachusetts
$4.04M +$804K +69,717 +33%
TCM
23
Tang Capital Management
California
$3.58M +$2.88M +250,000 New
SAM
24
Simplify Asset Management
Nevada
$3.41M – – –
Northern Trust
25
Northern Trust
Illinois
$3.11M +$49.4K +4,285 +2%
1
2 3 4 5

PHAT Hedge Fund Activity: Q2 2023 in Review

103 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Phathom Pharmaceuticals (PHAT) for Q2 2023, worth a combined $613M — up 179% from $220M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new PHAT positions and 9 closed out — a net gain of 19 holders — while 41 added to existing stakes and 20 trimmed.

The largest buyer was Frazier Life Sciences Management, adding an estimated $19.6M. The largest seller was Opaleye Management, exiting entirely with an estimated $3.54M sold.

  • 103 institutional investors held Phathom Pharmaceuticals (PHAT) as of Q2 2023, up from 84 in Q1 2023.
  • Funds reported $613M of Phathom Pharmaceuticals stock for Q2 2023, up 179% quarter-over-quarter.
  • 28 funds opened new Phathom Pharmaceuticals positions in Q2 2023 and 9 closed out, a net change of +19 holders.
  • The largest Phathom Pharmaceuticals buyer in Q2 2023 was Frazier Life Sciences Management, an estimated $19.6M added.
  • The largest Phathom Pharmaceuticals seller in Q2 2023 was Opaleye Management, an estimated $3.54M sold.

Based on aggregated 13F filings for Q2 2023.